Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DrFredC Digestix
- Development stage
- Unknown
- Lead developer
- IP Holdings
- Administration
- Oral
01
Overview
DrFredC Digestix is a dietary supplement developed by IP Holdings and marketed through the Xylonix platform. It features a patent-pending combination of activated charcoal, coffee bean fiber, and honey. The product is designed to address systemic inflammation by reducing gut-derived endotoxins, which in turn is intended to lower levels of interleukin-6 (IL-6). While it is commercially available and marketed for the potential relief of Long COVID symptoms and chronic conditions such as rheumatoid arthritis and Alzheimer's disease, it currently lacks direct clinical trial evidence for these specific indications.
- Brand names
- DrFredC Digestix
- Other names
- Digestix
02
Targets
IL-6 (Interleukin 6)
Beyond the preview
Go deeper on DrFredC Digestix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DrFredC Digestix.